Kalpataru Multiplier Ltd.

Our Bank & DP Click for Online Payment MF portfolio login smart way to invest in gold
Sovereign gold bond(SGB) Exchange trades funds(ETF)
CLOSE

Download our app Kalpataru Share trading from Google/App Store and transfer fund instantly.

Company Profile
more from company profile
HomeMarkets Company Profile Smart Quotes

Smart Quotes

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE2194.0531.15 (+1.44 %)
PREV CLOSE () 2162.90
OPEN PRICE () 2149.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 17490
TODAY'S LOW / HIGH ()2114.35 2202.50
52 WK LOW / HIGH ()1336.95 2297.2
NSE2193.1029.9 (+1.38 %)
PREV CLOSE() 2163.20
OPEN PRICE () 2153.40
BID PRICE (QTY) 2193.10 (1313)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 724078
TODAY'S LOW / HIGH() 2115.10 2205.00
52 WK LOW / HIGH ()1336 2297.9
BSE NSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone :

Registrar's Details : K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS
09Apr Glenmark Pharmaceuticals submits press
Glenmark Pharmaceuticals has submitted press release stating that Glenma..
09Apr Glenmark Pharmaceuticals gets USFDA’s
Glenmark Pharmaceuticals has received final approval from the United Sta..
23Mar Glenmark Pharmaceuticals launches GLIP
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for..
21Mar Glenmark Pharmaceuticals informs abou
Glenmark Pharmaceuticals has informed that the company research-led, glo..
19Mar Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc..
Financials
in Millions
QTR Dec 25 ANNUAL 25
Net Profit2820.6616103.5
Gross Profit 3465.27 21540.18
Operating Profit 6047.6226005.46
Net Sales 23599.3592264.09
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Astrazeneca Pharma I (BSE)
 8718.05 (5.14%)
M.Cap ( in Cr)
21795.13
Onesource Specialty (BSE)
 1543.30 (7.37%)
M.Cap ( in Cr)
17692.80
Ajanta Pharma (BSE)
 2895.85 (3.29%)
M.Cap ( in Cr)
36179.48
Venus Remedies (BSE)
 1039.95 (4.61%)
M.Cap ( in Cr)
1390.10
Acutaas Chemicals (BSE)
 2393.75 (1.27%)
M.Cap ( in Cr)
19597.90
Shareholding Pattern
PROMOTERS 46.65%
MUTUAL FUNDS/UTI 17.86%
NON-INSTITUTION 14.02%
FI/BANKS/INSURANCE 1.06%
GOVERNMENT 0.04%
FII 0%
Mf Holding
ATTENTION INVESTORS

Kalpataru Multiplier Ltd.

Kalpataru is a wishful Divine Tree and in present context a widely Trusted, Time tested and Transparent Share Broker, Mutual Fund Distributor and D.P. of this region.

Mobile Trading App
Mobile Trading IOS App
Call Us 0755-4350141/142/143, 9425008895
Mutual Funds 0755-4276725, 4276726
Email Uskmlho@kalpatarumulti.com

registration nos:

Kalpataru Multiplier Ltd.: SEBI Regn. No. INZ000259437

Registered address: Kalpataru House, 18 Itwara, Bhopal (MP) – 462001

Member Member ID
Bombay Stock Exchange Ltd.(BSE) 3016
National Stock Exchange Ltd. 11152
Multi Commodity Exchange(MCX) 16020

Depository Participant of CDSL DP-ID 12031600

(SEBI Regn No. IN-DP-CDSL-221-2003)

In absence of response/ complaint not addressed to your satisfaction, you may lodge a complaint and reach out to us on:

SMART ODR PORTAL @ https://smartodr.in/login

Copyright © 2016 Kalpataru Multiplier Ltd.
Designed ,Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
SENSEX76847.57-702.68 (-0.91%)
NIFTY23842.65-207.95 (-0.86%)
Dow Jones 48218.25301.68 (0.63%)
Nasdaq 23183.74280.85 (1.23%)
CLOSE Disclosure
CLOSE

INFORMATION UNDER THE HEAD SHOULD BE ADDED AS FOLLOWS

  • Sharing of trading credentials - login id & password including OTP's.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing / selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through Whatsapp, Telegram, YouTube, Facebook, SMS, Calls, etc.
  • Trading in "Options" based on recommendations from unauthorised / unregistered investment advisors and influencers.
CLOSE SEBI